(Companies Covered: MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, Sunshine Guojian Pharmaceutical)
The global interleukins market is expected to grow from $0.83 billion in 2019 to $1.6 billion in 2020 at a compound annual growth rate of 93.0%. The slow growth despite being launched in 2019 is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $5.81 million in 2023 at a compound annual growth rate of 53.64%.
Read More On The Global Biosimilar Interleukins Market Report At –
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukins-global-market-report-2020-30-covid-19-growth-and-change
The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases. Interleukin is a substance derived from white blood cells that enhances infection activity and is used to fight certain types of cancer.
Global Biosimilar Interleukins Market Segmentation –
1) By Type: IL-17, IL-23, IL-1, IL-5, IL-6, Others.
2) By Application: Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others.
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Clinics, Research Institutes.
Global Biosimilar Interleukins Market Driver –
The regulatory framework around the approval of interleukin biosimilars hampers the growth of the market. Biosimilars are manufactured with changes in the manufacturing process impacting the physicochemical and functional properties of a biologic drug and it is impractical to create an exact copy of the biologic drug. This compels the manufacturers to demonstrate biosimilarity between interleukin biosimilar and the biologic drug to prove that there are no clinically meaningful differences.
Request For A Sample Of The Global Biosimilar Interleukins Market Report At –
https://www.thebusinessresearchcompany.com/sample.aspx?id=3433&type=smp
Few Points From The Global Biosimilar Interleukins Market TOC
1. Executive Summary
2. Biosimilar Interleukins Market Characteristics
3. Biosimilar Interleukins Market Size And Growth
3.1. Global Biosimilar Interleukins Historic Market, 2015 – 2019, $ Billion
4. Biosimilar Interleukins Market Segmentation
4.1. Global Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5. Biosimilar Interleukins Market Regional And Country Analysis
5.1. Global Biosimilar Interleukins Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Biosimilar Interleukins Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6. Asia-Pacific Biosimilar Interleukins Market
6.1. Asia-Pacific Biosimilar Interleukins Market Overview
6.2. Asia-Pacific Biosimilar Interleukins Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
Media Contact
Company Name: The Business Research Company
Contact Person: Oliver Guirdham
Email: Send Email
Phone: +44 20 7193 0708
Address:
City: London
State: Greater London
Country: United Kingdom
Website: https://www.thebusinessresearchcompany.com/